Detalhe da pesquisa
1.
Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update.
Blood
; 143(17): 1713-1725, 2024 Apr 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38194692
2.
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
N Engl J Med
; 387(24): 2220-2231, 2022 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36507690
3.
Crosstalk between glucocorticoid and mineralocorticoid receptors boosts glucocorticoid-induced killing of multiple myeloma cells.
Cell Mol Life Sci
; 80(9): 249, 2023 Aug 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37578563
4.
RNA Extraction Method Impacts Quality Metrics and Sequencing Results in Formalin-Fixed, Paraffin-Embedded Tissue Samples.
Lab Invest
; 103(2): 100027, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37039153
5.
Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma.
Blood
; 137(26): 3616-3628, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33763699
6.
Many People With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Benefit From Ibrutinib Treatment Up To 8 Years: A Plain Language Summary.
Future Oncol
; 2023 01 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36617990
7.
Cusatuzumab for treatment of CD70-positive relapsed or refractory cutaneous T-cell lymphoma.
Cancer
; 128(5): 1004-1014, 2022 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34726773
8.
Shallow-depth sequencing of cell-free DNA for Hodgkin and diffuse large B-cell lymphoma (differential) diagnosis: a standardized approach with underappreciated potential.
Haematologica
; 107(1): 211-220, 2022 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33299235
9.
Identifying patients with chronic lymphocytic leukemia without need of treatment: End of endless watch and wait?
Eur J Haematol
; 108(5): 369-378, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-35030282
10.
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial.
Lancet Oncol
; 22(10): 1378-1390, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34529931
11.
Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma.
Future Oncol
; 17(11): 1295-1310, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33528286
12.
A five-year follow-up of untreated patients with chronic lymphocytic leukaemia treated with ofatumumab and chlorambucil: final analysis of the Complement 1 phase 3 trial.
Br J Haematol
; 190(5): 736-740, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32236950
13.
The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL.
Blood
; 132(23): 2446-2455, 2018 12 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30287523
14.
Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia: results from the pivotal phase III study COMPLEMENT1.
Haematologica
; 105(10): 2440-2447, 2020 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33054084
15.
The anaphase-promoting complex/cyclosome: a new promising target in diffuse large B-cell lymphoma and mantle cell lymphoma.
Br J Cancer
; 120(12): 1137-1146, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31089208
16.
A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts.
Lancet Oncol
; 19(4): 549-561, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29475724
17.
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
N Engl J Med
; 373(25): 2425-37, 2015 Dec 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-26639149
18.
Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2.
Haematologica
; 103(9): 1502-1510, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29880603
19.
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.
Lancet
; 387(10020): 770-8, 2016 Feb 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-26673811
20.
Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL.
Blood
; 126(16): 1893-901, 2015 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26232170